<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:npr="https://www.npr.org/rss/" xmlns:nprml="https://api.npr.org/nprml" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>NPR: Weight-loss drugs</title>
    <link>https://www.npr.org/templates/story/story.php?storyId=1172366859</link>
    <description>Weight-loss drugs</description>
    <language>en</language>
    <copyright>Copyright 2024 NPR - For Personal Use Only</copyright>
    <generator>Story API Shim 1.2.24</generator>
    <lastBuildDate>Wed, 09 Apr 2025 05:22:25 -0400</lastBuildDate>
    <image>
      <url>https://media.npr.org/images/podcasts/primary/npr_generic_image_300.jpg?s=200</url>
      <title>NPR: Weight-loss drugs</title>
      <link>https://www.npr.org/tags/1172366859/weight-loss-drugs</link>
    </image>
    <item>
      <title>Thin is back in, but did it ever leave us?</title>
      <description>When TikTok user, Slim Kim, posted a video expressing how much she loves &apos;being skinny,&apos; she set off a wave of internet discourse. What&apos;s the line between loving your body and dog-whistling fatphobia? This week, host Brittany Luse is joined by authors &lt;a href=&quot;https://www.vogue.com/contributor/emma-specter&quot;&gt;Emma Specter&lt;/a&gt; and &lt;a href=&quot;https://philosophy.cornell.edu/kate-manne&quot;&gt;Kate Manne&lt;/a&gt; to find out: what&apos;s so wrong with loving being skinny?&lt;br&gt;&lt;br&gt;Then, Brittany goes on a field trip to the Anime NYC convention. She and IBAM producer Alexis Williams venture out to find out how generations of Black folks have found comfort, confidence, and fandom in the genre.&lt;br&gt;&lt;br&gt;Support public media and receive ad-free listening &amp; bonus content by joining NPR+ today: &lt;a href=&quot;https://plus.npr.org/&quot;&gt;https://plus.npr.org/&lt;/a&gt;</description>
      <pubDate>Fri, 06 Dec 2024 03:00:14 -0500</pubDate>
      <link>https://www.npr.org/2024/12/06/1217547155/skinny-fascism-black-anime</link>
      <guid>https://www.npr.org/2024/12/06/1217547155/skinny-fascism-black-anime</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2024/12/06/friday-artwork-ozempic_wide-18e5c69f1d9244ffa34e6e55f1425e4b17971b11.jpg' alt='With the rise of shapewear and GLP-1s, is the end of the body positivity movement the beginning of "body fascism?"'/><p>When TikTok user, Slim Kim, posted a video expressing how much she loves 'being skinny,' she set off a wave of internet discourse. What's the line between loving your body and dog-whistling fatphobia? This week, host Brittany Luse is joined by authors <a href="https://www.vogue.com/contributor/emma-specter">Emma Specter</a> and <a href="https://philosophy.cornell.edu/kate-manne">Kate Manne</a> to find out: what's so wrong with loving being skinny?<br><br>Then, Brittany goes on a field trip to the Anime NYC convention. She and IBAM producer Alexis Williams venture out to find out how generations of Black folks have found comfort, confidence, and fandom in the genre.<br><br>Support public media and receive ad-free listening & bonus content by joining NPR+ today: <a href="https://plus.npr.org/">https://plus.npr.org/</a></p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1217547155' />]]></content:encoded>
      <dc:creator>Brittany Luse</dc:creator>
    </item>
    <item>
      <title>Dizzy after one drink? Social drinkers on obesity drugs lose the taste for alcohol</title>
      <description>A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could be a promising new treatment for addiction.</description>
      <pubDate>Mon, 02 Dec 2024 05:00:00 -0500</pubDate>
      <link>https://www.npr.org/sections/shots-health-news/2024/12/02/nx-s1-5205478/alcohol-weight-loss-medication-ozempic-wegovy</link>
      <guid>https://www.npr.org/sections/shots-health-news/2024/12/02/nx-s1-5205478/alcohol-weight-loss-medication-ozempic-wegovy</guid>
      <content:encoded><![CDATA[<img src='https://npr.brightspotcdn.com/dims3/default/strip/false/crop/2120x1414+0+0/resize/2120x1414!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F65%2Fb8%2Ff67b44a348da8e1c68f767b97718%2Fgettyimages-1937536154.jpg' alt='Moderate drinkers who also take weight-loss drugs like Mounjaro, report drinking less alcohol, a new study finds.'/><p>A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could be a promising new treatment for addiction.</p><p>(Image credit: AzmanJaka)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=nx-s1-5205478' />]]></content:encoded>
      <dc:creator>Allison Aubrey</dc:creator>
    </item>
    <item>
      <title>Ozempic shows promise for alcohol and drug addiction, study finds</title>
      <description>The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too. </description>
      <pubDate>Fri, 18 Oct 2024 11:11:18 -0400</pubDate>
      <link>https://www.npr.org/sections/shots-health-news/2024/10/18/nx-s1-5156068/ozempic-semaglutide-alcohol-drug-treatment</link>
      <guid>https://www.npr.org/sections/shots-health-news/2024/10/18/nx-s1-5156068/ozempic-semaglutide-alcohol-drug-treatment</guid>
      <content:encoded><![CDATA[<img src='https://npr.brightspotcdn.com/dims3/default/strip/false/crop/2120x1414+0+0/resize/2120x1414!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F6d%2F62%2F12f99338426f941667f5869391cd%2Fgettyimages-1054068154.jpg' alt='People with prescriptions for Ozempic and similar drugs had lower rates of intoxication and drug overdoses, according to a new study.'/><p>The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too. </p><p>(Image credit: 5m3photos)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=nx-s1-5156068' />]]></content:encoded>
      <dc:creator>Maria Godoy</dc:creator>
    </item>
    <item>
      <title>After nearly a decade, Oprah Winfrey is set to depart the board of WeightWatchers</title>
      <description>The announcement comes amid falling profits for the company. WeightWatchers has been facing declining stock prices since November as weight loss drugs, known as GLP1s, have soared in popularity.</description>
      <pubDate>Fri, 01 Mar 2024 16:38:28 -0500</pubDate>
      <link>https://www.npr.org/2024/03/01/1235100405/after-nearly-a-decade-oprah-winfrey-is-set-to-depart-the-board-of-weightwatchers</link>
      <guid>https://www.npr.org/2024/03/01/1235100405/after-nearly-a-decade-oprah-winfrey-is-set-to-depart-the-board-of-weightwatchers</guid>
      <content:encoded><![CDATA[<p>The announcement comes amid falling profits for the company. WeightWatchers has been facing declining stock prices since November as weight loss drugs, known as GLP1s, have soared in popularity.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1235100405' />]]></content:encoded>
      <dc:creator>Vanessa Romo</dc:creator>
    </item>
    <item>
      <title>Weight-loss drugs aren&apos;t a magic bullet. Lifestyle changes are key to lasting health</title>
      <description>A doctor argues that the current focus on fighting obesity with drugs like Ozempic ignores the bigger picture: We need a medical system and society that support healthy life habits.</description>
      <pubDate>Mon, 12 Feb 2024 05:01:11 -0500</pubDate>
      <link>https://www.npr.org/sections/health-shots/2024/02/12/1229920739/weight-loss-drugs-ozempic-arent-magic-bullet-lifestyle-changes-lasting-health</link>
      <guid>https://www.npr.org/sections/health-shots/2024/02/12/1229920739/weight-loss-drugs-ozempic-arent-magic-bullet-lifestyle-changes-lasting-health</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2024/02/07/gettyimages-1875370772-15eca4f4664a2a0b4497462b9215972e91308a86.jpg' alt='undefined'/><p>A doctor argues that the current focus on fighting obesity with drugs like Ozempic ignores the bigger picture: We need a medical system and society that support healthy life habits.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1229920739' />]]></content:encoded>
      <dc:creator>Lisa Doggett</dc:creator>
    </item>
    <item>
      <title>Who can and cannot get weight-loss drugs</title>
      <description>Drugs used for weight loss like Wegovy, Ozempic and Mounjaro are nearly everywhere in popular culture, but many patients struggling with obesity are still finding them hard to get. On today&apos;s show, what&apos;s slowing access to these drugs despite their long-term benefits for the economy and patients, and how social conditioning around obesity and excess weight clouds the conversation. &lt;br&gt;&lt;br&gt;&lt;strong&gt;Related Episodes:&lt;br&gt;&lt;/strong&gt;New drugs. Cheaper drugs. Why not both? (&lt;a href=&quot;https://podcasts.apple.com/us/podcast/the-indicator-from-planet-money/id1320118593?i=1000604400111&quot;&gt;Apple&lt;/a&gt; / &lt;a href=&quot;https://open.spotify.com/episode/0S8lY9cpBg2EBYI0UekNrh?si=GhFkWFK5S464AoiHW3Rrjw&quot;&gt;Spotify&lt;/a&gt;) &lt;br&gt;&lt;br&gt;&lt;em&gt;For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at &lt;/em&gt;&lt;a href=&quot;http://plus.npr.org/&quot;&gt;&lt;em&gt;plus.npr.org&lt;/em&gt;&lt;/a&gt;&lt;em&gt;. &lt;br&gt;&lt;br&gt;Music by &lt;/em&gt;&lt;a href=&quot;https://dropelectric.bandcamp.com/&quot;&gt;&lt;em&gt;Drop Electric&lt;/em&gt;&lt;/a&gt;&lt;em&gt;. Find us: &lt;/em&gt;&lt;a href=&quot;https://www.tiktok.com/@planetmoney&quot;&gt;&lt;em&gt;TikTok&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.instagram.com/planetmoney/&quot;&gt;&lt;em&gt;Instagram&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.facebook.com/planetmoney&quot;&gt;&lt;em&gt;Facebook&lt;/em&gt;&lt;/a&gt;, &lt;a href=&quot;https://www.npr.org/newsletter/money&quot;&gt;&lt;em&gt;Newsletter&lt;/em&gt;&lt;/a&gt;.</description>
      <pubDate>Mon, 04 Dec 2023 18:27:42 -0500</pubDate>
      <link>https://www.npr.org/2023/12/04/1197958695/semaglutide-weight-loss-drugs-and-health-insurers</link>
      <guid>https://www.npr.org/2023/12/04/1197958695/semaglutide-weight-loss-drugs-and-health-insurers</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/12/04/gettyimages-1305152135-d946205bc2e61f32151264c11031bb5361cdfe8f.jpg' alt='undefined'/><p>Drugs used for weight loss like Wegovy, Ozempic and Mounjaro are nearly everywhere in popular culture, but many patients struggling with obesity are still finding them hard to get. On today's show, what's slowing access to these drugs despite their long-term benefits for the economy and patients, and how social conditioning around obesity and excess weight clouds the conversation. <br><br><strong>Related Episodes:<br></strong>New drugs. Cheaper drugs. Why not both? (<a href="https://podcasts.apple.com/us/podcast/the-indicator-from-planet-money/id1320118593?i=1000604400111">Apple</a> / <a href="https://open.spotify.com/episode/0S8lY9cpBg2EBYI0UekNrh?si=GhFkWFK5S464AoiHW3Rrjw">Spotify</a>) <br><br><em>For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at </em><a href="http://plus.npr.org/"><em>plus.npr.org</em></a><em>. <br><br>Music by </em><a href="https://dropelectric.bandcamp.com/"><em>Drop Electric</em></a><em>. Find us: </em><a href="https://www.tiktok.com/@planetmoney"><em>TikTok</em></a>, <a href="https://www.instagram.com/planetmoney/"><em>Instagram</em></a>, <a href="https://www.facebook.com/planetmoney"><em>Facebook</em></a>, <a href="https://www.npr.org/newsletter/money"><em>Newsletter</em></a>.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1197958695' />]]></content:encoded>
      <dc:creator>Paddy Hirsch</dc:creator>
    </item>
    <item>
      <title>I try to be a body-positive doctor. It&apos;s getting harder in the age of Ozempic</title>
      <description>A physician decided to stop talking to patients about weight, and focus on health instead. But the new weight-loss drugs forced her to rethink how to help patients without feeding into stigma.</description>
      <pubDate>Wed, 04 Oct 2023 09:00:45 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/10/04/1202723479/ozempic-body-positive-medicine-weight-stigma</link>
      <guid>https://www.npr.org/sections/health-shots/2023/10/04/1202723479/ozempic-body-positive-medicine-weight-stigma</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/10/03/finalv2_custom-bb57bfe2f93a6ef8a454b3eef2844a4459a857e3.jpg' alt='undefined'/><p>A physician decided to stop talking to patients about weight, and focus on health instead. But the new weight-loss drugs forced her to rethink how to help patients without feeding into stigma.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1202723479' />]]></content:encoded>
      <dc:creator>Mara Gordon</dc:creator>
    </item>
    <item>
      <title>Ozempic seems to curb cravings for alcohol. Here&apos;s what scientists think is going on</title>
      <description>People taking weight-loss drugs Ozempic and Wegovy report a dampening of the urge to drink. Here&apos;s how the drugs curb cravings and what that could mean for helping treat addiction.</description>
      <pubDate>Mon, 28 Aug 2023 05:00:50 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/08/28/1194526119/ozempic-wegovy-drinking-alcohol-cravings-semaglutide</link>
      <guid>https://www.npr.org/sections/health-shots/2023/08/28/1194526119/ozempic-wegovy-drinking-alcohol-cravings-semaglutide</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/08/19/gettyimages-1331114824-c8715ff650fb86503ce87b2f179d5b234e2902b5.jpg' alt='Some people who take Ozempic and Wegovy report it tamps down their cravings for alcohol, and they're drinking less.'/><p>People taking weight-loss drugs Ozempic and Wegovy report a dampening of the urge to drink. Here's how the drugs curb cravings and what that could mean for helping treat addiction.</p><p>(Image credit: lucentius)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1194526119' />]]></content:encoded>
      <dc:creator>Michaeleen Doucleff</dc:creator>
    </item>
    <item>
      <title>Lifesaving or stigmatizing? Parents wrestle with obesity treatment options for kids</title>
      <description>New weight-loss medications and bariatric surgery have the potential to spare children health and social problems. But some parents think they&apos;re sending kids the wrong message about their bodies.</description>
      <pubDate>Tue, 16 May 2023 05:28:07 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/05/16/1169699513/wegovy-weight-loss-drugs-kids-bariatric-surgery</link>
      <guid>https://www.npr.org/sections/health-shots/2023/05/16/1169699513/wegovy-weight-loss-drugs-kids-bariatric-surgery</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/04/13/obesity-treatments-kids_wide-06c4b7e5b5f703439d7f7b84463e7eac47a9c0ce.jpg' alt='undefined'/><p>New weight-loss medications and bariatric surgery have the potential to spare children health and social problems. But some parents think they're sending kids the wrong message about their bodies.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1169699513' />]]></content:encoded>
      <dc:creator>Yuki Noguchi</dc:creator>
    </item>
    <item>
      <title>Eli Lilly releases more data for new obesity drug, moving toward fast-track approval</title>
      <description>There&apos;s already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.</description>
      <pubDate>Thu, 27 Apr 2023 06:16:01 -0400</pubDate>
      <link>https://www.npr.org/sections/health-shots/2023/04/27/1172365791/eli-lilly-releases-more-data-for-new-obesity-drug-moving-toward-fast-track-appro</link>
      <guid>https://www.npr.org/sections/health-shots/2023/04/27/1172365791/eli-lilly-releases-more-data-for-new-obesity-drug-moving-toward-fast-track-appro</guid>
      <content:encoded><![CDATA[<img src='https://media.npr.org/assets/img/2023/04/26/eli-lilly-headquarters-e90772a3f74e1070aba4691b41103795fdc51ab8.jpg' alt='Eli Lilly is seeking FDA approval for tirzepatide for chronic weight management. The drug could be approved by the end of the year.'/><p>There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=1172365791' />]]></content:encoded>
      <dc:creator>Allison Aubrey</dc:creator>
    </item>
  </channel>
</rss>